Dupilumab Improves Histopathologic Aspects of Eosinophilic Esophagitis: Results of a Pooled Analysis From the EoE KIDS and LIBERTY EoE TREET Phase 3 Studies (CAP 2026) - Aug 26, 2026 - Abstract #Poster No. 10; Pres time: Oct 4, 2026; 11:30 AM - 01:00 PM; Location: Cristal Ballroom Exhibit Hall; P3 | "Falk Pharma, Ferring, GI Reviewers, GSK, Holoclara, Invea, Knightpoint, LucidDx, Nexstone Immunology/Uniquity, Nutricia, Parexel/Calyx, Phathom, Regeneron, Revolo, Robarts/Alimentiv, Roivant, Sanofi, Shire/Takeda, Target RWE, Third Harmonic Bio, and Upstream Bio; and research support from Adare/Ellodi, Allakos, Arena/Pfizer, AstraZeneca, Celgene/Receptos/BMS, Celldex, Dr. In this pooled analysis of 2 phase-3 studies, dupilumab improved histopathologic abnormalities of EoE during treatment initiation, compared with placebo (W16/24) and maintenance (W52) in patients with EoE. Supported Collins received a consulting fee from Alimentiv, Arena/Pfizer, AstraZeneca, Calypso Biotech, EsoCap Biotech, GSK, Receptos/Celgene/Bristol Myers Squibb, Regeneron Pharmaceuticals Inc, Sanofi, and Shire (a Takeda company). Chehade received a consulting fee from Adare Pharma Solutions/Ellodi Pharmaceuticals, Allakos, Apogee Therapeutics, AstraZeneca, Bristol Myers Squibb,...
P3 data • Retrospective data • Eosinophilic Esophagitis • Gastrointestinal Disorder • Immunology
|
|
Margaret H. Collins, MD1; Mirna Chehade, MD, MPH2; Evan S. Dellon, MD3; Christoph Schlag, MD4; Matteo Fassan, MD, PhD5; M. K. Washington, MD, PhD6; Changming Xia, PhD7; Sherif Zaghloul, MD, MSc8; Bram P. Raphael, MD9; Cristina Almansa, MD, PhD10; Amr Radwan, MA, MBBChir.11
|